TSBX
NASDAQTurnstone Biologics Corp.
Turnstone Biologics Corp. (TSBX) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. There were no new wire items for TSBX in the last 30 days. The most recent was published Aug 21, 2025.
Latest news
25 items- SECSEC Form 15-12G filed by Turnstone Biologics Corp.15-12G - Turnstone Biologics Corp. (0001764974) (Filer)
- INSIDERSEC Form 4 filed by Director Orbimed Advisors Llc4 - Turnstone Biologics Corp. (0001764974) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Turnstone Biologics Corp.SCHEDULE 13D/A - Turnstone Biologics Corp. (0001764974) (Subject)
- INSIDERSEC Form 4 filed by Large owner Versant Ventures V, Llc4 - Turnstone Biologics Corp. (0001764974) (Issuer)
- SECSEC Form S-8 POS filed by Turnstone Biologics Corp.S-8 POS - Turnstone Biologics Corp. (0001764974) (Filer)
- SECSEC Form S-8 POS filed by Turnstone Biologics Corp.S-8 POS - Turnstone Biologics Corp. (0001764974) (Filer)
- SECTurnstone Biologics Corp. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant8-K - Turnstone Biologics Corp. (0001764974) (Filer)
- SECAmendment: SEC Form SC 14D9/A filed by Turnstone Biologics Corp.SC 14D9/A - Turnstone Biologics Corp. (0001764974) (Subject)
- SECSEC Form 25-NSE filed by Turnstone Biologics Corp.25-NSE - Turnstone Biologics Corp. (0001764974) (Subject)
- SECAmendment: SEC Form SC TO-T/A filed by Turnstone Biologics Corp.SC TO-T/A - Turnstone Biologics Corp. (0001764974) (Subject)
- PRXOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics- Turnstone Stockholders Received $0.34 Per Share in Cash Plus Contingent Value Right - EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty" or the "Company"), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company has successfully completed its previously announced tender offer to acquire all outstanding shares of Turnstone Biologics Corp. (NASDAQ:TSBX) common stock for a price per share of $0.34 in cash (the "Cash Amount"), plus one non-tradeable contingent value right ("CVR" and together with the Cash Amount, the "Offer Pr
- SECSEC Form 10-Q filed by Turnstone Biologics Corp.10-Q - Turnstone Biologics Corp. (0001764974) (Filer)
- INSIDERSEC Form 4 filed by Director Jerel Davis4 - Turnstone Biologics Corp. (0001764974) (Issuer)
- INSIDERSEC Form 4 filed by Director Gupta Rishi4 - Turnstone Biologics Corp. (0001764974) (Issuer)
- SECAmendment: SEC Form SC 14D9/A filed by Turnstone Biologics Corp.SC 14D9/A - Turnstone Biologics Corp. (0001764974) (Subject)
- SECAmendment: SEC Form 8-K/A filed by Turnstone Biologics Corp.8-K/A - Turnstone Biologics Corp. (0001764974) (Filer)
- SECSEC Form SC 14D9 filed by Turnstone Biologics Corp.SC 14D9 - Turnstone Biologics Corp. (0001764974) (Subject)
- SECSEC Form SC TO-T filed by Turnstone Biologics Corp.SC TO-T - Turnstone Biologics Corp. (0001764974) (Subject)
- SECAmendment: SEC Form 8-K/A filed by Turnstone Biologics Corp.8-K/A - Turnstone Biologics Corp. (0001764974) (Filer)
- SECTurnstone Biologics Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure8-K - Turnstone Biologics Corp. (0001764974) (Filer)
- SECSEC Form SC14D9C filed by Turnstone Biologics Corp.SC14D9C - Turnstone Biologics Corp. (0001764974) (Subject)
- SECSEC Form SC TO-C filed by Turnstone Biologics Corp.SC TO-C - Turnstone Biologics Corp. (0001764974) (Subject)
- PRTurnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value RightEMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX) today announced that they have entered into a definitive merger agreement ("the Merger Agreement"), whereby XOMA Royalty will acquire Turnstone for $0.34 in cash per share of Turnstone common stock ("Turnstone common stock") plus one non-transferable contingent value right ("CVR"). Following a thorough review process conducted with the assistance of its legal and financial advisors, the Turnstone Board of Directors has unanimously determined that the acquisition by XOMA Royalty is in the best
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Turnstone Biologics Corp.SCHEDULE 13G/A - Turnstone Biologics Corp. (0001764974) (Subject)
- PRTurnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate HighlightsSAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte ("Selected TIL") therapy, today reported financial results for the first quarter ended March 31, 2025, and provided recent corporate updates. Corporate Updates In January 2025, Turnstone made the determination to discontinue all TIDAL-01 clinical studies and halted further development of the program. As a result, the Company initiated a process to explore a range of potentia
TSBX FAQ
7 questionsWhat is the latest news on TSBX?
Quantisnow has not tracked any new filings, ratings or press releases for TSBX in the last 30 days. The most recent wire item was published on August 21, 2025.Where does TSBX stock trade?
Turnstone Biologics Corp. (TSBX) is listed on NASDAQ.What sector and industry is TSBX in?
Turnstone Biologics Corp. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Turnstone Biologics Corp. go public?
Turnstone Biologics Corp. (TSBX) completed its IPO in 2023.What are analysts saying about TSBX?
Across the last 6 analyst actions on Turnstone Biologics Corp., there were 0 upgrades and 3 downgrades. The most recent action was from Piper Sandler: Neutral with a $0.40 price target on 2025-02-05.What companies are similar to TSBX?
Notable peers in the same industry include AMGN (Amgen Inc.), ARGX (argenx SE), MRNA (Moderna Inc.), RVMD (Revolution Medicines Inc.), GILD (Gilead Sciences Inc.). Compare TSBX side-by-side with any of them on Quantisnow.How can I track TSBX on Quantisnow?
Quantisnow aggregates Turnstone Biologics Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TSBX to receive live email and push alerts on every new disclosure.